[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100581542":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":43,"centralContacts":51,"locations":57,"responsibleParty":78,"collaborators":55,"id":80,"slug":81,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":55,"eligibilityCriteria":85,"healthyVolunteers":82,"sex":86,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":55,"studyType":92,"phases":93,"briefSummary":96,"conditions":97,"keywords":112,"overallStatus":60,"whyStopped":55,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":124},{"fullName":5,"class":6},"RenJi Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Trop2-targeted immunoPET imaging","EXPERIMENTAL","Enrolled patients will undergo a Trop2-targeted immunoPET\u002FCT scanning.",[13,14,15,16],"Drug: [68Ga]Ga-NOTA-T4","Drug: [68Ga]Ga-NOTA-RT4","Drug: [18F]F-RESCA-T4","Drug: [18F]F-RESCA-RT4",[18,25,31,37],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"DRUG","[68Ga]Ga-NOTA-T4","Enrolled patients will receive 0.05-0.1 mCi\u002Fkg of \\[68Ga\\]Ga-NOTA-T4. ImmunoPET\u002FCT imaging will be acquired 1-2 hours after \\[68Ga\\]Ga-NOTA-T4 injection.",[9],[24],"[68Ga]T4",{"type":19,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"[68Ga]Ga-NOTA-RT4","Enrolled patients will receive 0.05-0.1 mCi\u002Fkg of \\[68Ga\\]Ga-NOTA-RT4. ImmunoPET\u002FCT imaging will be acquired 1-2 hours after \\[68Ga\\]Ga-NOTA-RT4 injection.",[9],[30],"[68Ga]RT4",{"type":19,"name":32,"description":33,"armGroupLabels":34,"otherNames":35},"[18F]F-RESCA-T4","Enrolled patients will receive 0.05-0.1 mCi\u002Fkg of \\[18F\\]F-RESCA-T4. ImmunoPET\u002FCT imaging will be acquired 1-2 hours after \\[18F\\]F-RESCA-T4 injection.",[9],[36],"[18F]T4",{"type":19,"name":38,"description":39,"armGroupLabels":40,"otherNames":41},"[18F]F-RESCA-RT4","Enrolled patients will receive 0.05-0.1 mCi\u002Fkg of \\[18F\\]F-RESCA-RT4. ImmunoPET\u002FCT imaging will be acquired 1-2 hours after \\[18F\\]F-RESCA-RT4 injection.",[9],[42],"[18F]RT4",[44,48],{"name":45,"affiliation":46,"role":47},"Jianjun Liu, Ph.D. & M.D.","Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University","STUDY_CHAIR",{"name":49,"affiliation":46,"role":50},"Weijun Wei, Ph.D. & M.D.","PRINCIPAL_INVESTIGATOR",[52],{"name":49,"role":53,"phone":54,"phoneExt":55,"email":56},"CONTACT","15000083153",null,"wwei@shsmu.edu.cn",[58],{"facility":59,"status":60,"city":61,"state":55,"zip":62,"country":63,"countryCode":64,"cosmosGeoPoint":65,"geoPoint":70,"contacts":71},"Renji Hospital, School of Medicine, Shanghai Jiao Tong University","RECRUITING","Shanghai","200127","China","CN",{"type":66,"coordinates":67},"Point",[68,69],121.45806,31.22222,{"lat":69,"lon":68},[72,74],{"name":73,"role":53,"phone":54,"phoneExt":55,"email":56},"Weijun Wei",{"name":75,"role":53,"phone":76,"phoneExt":55,"email":77},"Shuxian An","17717453484","anshuxian@shsmu.edu.cn",{"type":79,"investigatorFullName":55,"investigatorTitle":55,"investigatorAffiliation":55,"oldNameTitle":55,"oldOrganization":55},"SPONSOR","100581542","phase-2-trop2-targeted-immunopet-imaging-of-solid-tumors-100581542",false,"NCT06851663","Trop2-targeted immunoPET Imaging of Solid Tumors","Inclusion Criteria:\n\n* Aged 18-75 year-old and of either sex\n* Histologically confirmed diagnosis of solid tumors (including uroepithelial cancer, bladder cancer, prostate cancer, lung cancer, nasopharyngeal cancer, liver cancer, cholangiocarcinoma, ovarian cancer, cervical cancer, endometrial cancer, thyroid cancer, head and neck cancer) or suspected solid tumors (including uroepithelial cancer, bladder cancer, prostate cancer, lung cancer, nasopharyngeal cancer, liver cancer, cholangiocarcinoma, ovarian cancer, cervical cancer, endometrial cancer, thyroid cancer, head and neck cancer) by diagnostic imaging;\n* Capable of giving signed informed consent, including compliance with the requirements and restrictions in the informed consent form (ICF) and this protocol.\n\nExclusion Criteria:\n\n* Pregnancy；\n* Severe hepatic and renal insufficiency;\n* Allergic to single-domain antibody radiopharmaceuticals.","ALL","18 Years","75 Years",{"count":90,"type":91},400,"ESTIMATED","INTERVENTIONAL",[94,95],"PHASE2","PHASE3","This study aims to establish and optimize the trophoblast cell surface antigen 2 (Trop2)-targeted immuno-positron emission tomography\u002Fcomputed tomography (immunoPET\u002FCT) imaging method and its physiological and pathological distribution characteristics, based on which the diagnostic efficacy of the above imaging agents in solid tumors (including uroepithelial cancer, bladder cancer, prostate cancer, lung cancer, nasopharyngeal cancer, liver cancer, cholangiocarcinoma, ovarian cancer, cervical cancer, endometrial cancer, thyroid cancer, head and neck cancer) will be evaluated.",[98,99,100,101,102,103,104,105,106,107,108,109,110,111],"Solid Tumor","Solid Carcinoma","Uroepithelial Carcinoma","Bladder Cancer","Prostate Cancer","Lung Cancer","Nasopharyngeal Cancer","Liver Cancer","Cholangiocarcinoma","Ovarian Cancer","Cervical Cancer","Endometrial Cancer","Thyroid Cancer","Head and Neck Cancer",[113,114,98],"Trophoblast cell surface antigen 2 (Trop2)","ImmunoPET","2026-05-27",{"date":117,"type":118},"2026-05-29","ACTUAL",{"date":120,"type":118},"2024-12-23",{"date":122,"type":91},"2027-12",{"name":5,"class":6},1]